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Purpose: Hyperglycemia increases reactive oxygen species (ROS) and the result-
ing oxidative stress plays a key role in the pathogenesis of diabetic complications. 
Nicotinamide dinucleotide phosphate (NADPH) oxidase is one of the major sourc-
es of ROS production in diabetes. We, therefore, examined the possibility that 
NADPH oxidase activation is increased in various tissues, and that the antioxidant 
N-acetylcysteine (NAC) may have tissue specific effects on NADPH oxidase and 
tissue antioxidant status in diabetes. Materials and Methods: Control (C) and 
streptozotocin-induced diabetic (D) rats were treated either with NAC (1.5 g/kg/
day) orally or placebo for 4 weeks. The plasma, heart, lung, liver, kidney were har-
vested immediately and stored for biochemical or immunoblot analysis. Results: 
levels of free 15-F2t-isoprostane were increased in plasma, heart, lung, liver and 
kidney tissues in diabetic rats, accompanied with significantly increased mem-
brane translocation of the NADPH oxidase subunit p67phox in all tissues and in-
creased expression of the membrane-bound subunit p22phox in heart, lung and 
kidney. The tissue antioxidant activity in lung, liver and kidney was decreased in 
diabetic rats, while it was increased in heart tissue. NAC reduced the expression of 
p22phox and p67phox, suppressed p67phox membrane translocation, and reduced 
free 15-F2t-isoprostane levels in all tissues. NAC increased antioxidant activity in 
liver and lung, but did not significantly affect antioxidant activity in heart and kid-
ney. Conclusion: The current study shows that NAC inhibits NADPH oxidase ac-
tivation in diabetes and attenuates tissue oxidative damage in all organs, even 
though its effects on antioxidant activity are tissue specific.
Key Words:    Antioxidant status, diabetes, 15-F2t-isoprostane, N-acetylcysteine, 
NADPH oxidase
INTRODUCTION
Diabetes mellitus is a serious metabolic disease, and the number of people with di-
abetes is rapidly increasing due to population growth, aging, urbanization, and in- NADPH Oxidase Activation in Diabetic Rats
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effectiveness of antioxidant therapies. During early diabe-
tes, various tissues may enhance their antioxidant enzymes 
activity to withstand hyperglycemia-induced ROS produc-
tion. However, little is known regarding the tissue specific 
changes of overall antioxidant capacity and the underlying 
mechanism in early diabetes.
We hypothesized that changes in the levels of both NADPH 
oxidase and SOD may be tissue specific, possibly having a 
significant impact on the total tissue antioxidant activity 
and on the effectiveness of antioxidant treatment in early 
diabetes. Therefore, this hypothesis was tested in an estab-
lished rat model of STZ-induced type 1 diabetes. Since glu-
tathione (GSH) depletion may play an important role in the 
development of diabetic complications23 and GSH deple-
tion occurs in early diabetes,24 we also explored the treat-
ment effects of N-acetylcystein, a GSH precursor that can 
enhance the GSH antioxidant defense.25 
MATERIALS AND METHODS
　　　
Experiment design and induction of diabetes
Sprague-Dawley male rats aged 8 weeks and weighing 250 
to 280 gram were purchased from the Animal Unit of Wu-
han University, China, and allowed to adapt in their cages 
for three days before experiments. All rats had free access 
to standard chow and water. The experiments were per-
formed in accordance with our institutional animal care 
guidelines which are in line with the use of Laboratory Ani-
mals published by the US National Institutes of Health. The 
study was approved by Institutional Animal Care and Use 
Committee.
Diabetes was induced by a single tail vein injection (un-
der halothane anaesthesia) of streptozotocin (Sigma, St. 
Louis, MO, USA) (STZ, 60 mg/kg body weight, freshly dis-
solved in 0.1 M citrate buffer, pH 4.5), while control rats 
(n=7) were injected equal volume citrate buffer alone. Three 
days following STZ injection, blood glucose levels were 
measured using a Glucose Analyzer (Beckman Instruments, 
Fullerton, CA,  USA), and rats with hyperglycemia (set at 
plasma glucose ≥16.7 mM) were used for the experiments.
NAC, at the dose of 1.5 g/kg/day, had no effects on NADPH 
oxidase activity and SOD activity in non-diabetic control 
rats but had effects on these parameters in diabetic rats.16 In 
the current study, therefore, NAC was used only in diabetic 
rats. One week after the induction of diabetes, rats were 
randomly assigned into NAC-treated or untreated groups 
creasing prevalence of obesity.1,2 Hyperglycaemia-induced 
oxidative stress, as a result of excessive production of reac-
tive oxygen species (ROS), plays a key role in the patho-
genesis of diabetes-related complications.3-5 Theoretically, 
suppression of oxidative stress using antioxidants should 
reverse adverse effects induced by hyperglycaemia in dia-
betic patients. However, large randomized clinical trials 
have failed to provide convincing evidence for effective an-
tioxidant therapy with classic antioxidants, such as vitamins 
E and C.6-8 Therefore, development of new therapeutic re-
gimes is important for patients with diabetes.
Oxidative stress results from increased production of 
ROS or diminished antioxidant capacity in cells or tissues. 
One of the major sources of ROS in tissues of diabetic pa-
tients is nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase.9,10 NADPH oxidase contains two mem-
brane-bound subunits gp91phox (Nox2) and p22phox and 
cytoplasmic subunits such as p47phox, p67phox and a low-
molecular-weight G protein (rac 1 and rac 2).11 NADPH 
oxidase catalyzes the generation of superoxide anion using 
NADPH as the electron donor in cells.12 Superoxide is well 
known to be a mediator of inflammation and an inducer of 
apoptosis. Expression or activation of NADPH oxidase is 
increased in diabetes or high-glucose treated endothelial 
cells.13-15 We previously showed that long term treatment 
with the antioxidant N-acetylcysteine (NAC) could inhibit 
NADPH oxidase activation in the heart of diabetic rats, and 
it also abolished the compensatory increase in the antioxi-
dant enzyme superoxide dismutase (SOD).16 It is, however, 
unknown whether or not short term NAC treatment may 
preserve the compensatory increase of endogenous SOD 
protein expression in diabetes, while maintaining its inhibi-
tory effects on NADPH oxidase activation. 
SOD, including cytosolic Cu/Zn-SOD, mitochondrial 
Mn-SOD and extracellular SOD,17 are enzymes involved in 
the scavenging of superoxide anions and play an important 
role in balancing ROS generation. Superoxide anions are 
mainly generated by the mitochondrial electron transport 
chain and are implicated in the progression of diabetes.18-20 
Increased ROS production in diabetes can be prevented by 
the administration of SOD.21 A recent study showed that to-
tal SOD activity and extracellular Cu/Zn-SOD activity were 
reduced, whereas Mn-SOD activity was increased in the 
heart of long-term diabetic rats.22 This indicates that indi-
vidual endogenous tissue antioxidant enzymes and poten-
tially the total tissue antioxidant activity may change differ-
ently in diabetes. This complexity may potentially affect the Shaoqing Lei, et al.
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dant Status Assay Kit (Calbiochem, Darmstadt, Germany), 
which is dependent on the capacity in the sample to inhibit the 
oxidation of ABTSTM [2,2’-Azino-di-(3-ethylbenz-thiazoline 
sulphonate)] to ABTSTM•+ by metmyoglobin (a peroxidase). 
The amount of ABTSTM•+ produced can be monitored by 
reading absorbance at 600 nm. Under the reaction conditions 
used, the antioxidants in the sample suppress absorbance at 
600 nm by the degree proportional to their concentration. To-
tal antioxidant activity was calculated and expressed as milli-
mole per liter (mM) in plasma or millimole per gram protein 
in tissue samples (mmol/g protein).   
Total superoxide dismutase activity assay
SOD activity was determined using a Superoxide Dismutase 
Assay Kit (Cayman chemical, Ann Arbor, MI, USA) fol-
lowing the manufacturer’s instructions. Plasma samples 
were assayed immediately after being thawed. Tissue sec-
tions (50 mg) were homogenized in 1 mL of cold 20 mM 
HEPES buffer, pH 7.2, containing 1 mM EGTA, 210 mM 
mannitol and 70 mM sucrose, and centrifuged at 1500×g 
for 5 min at 4°C, and the supernatants were collected for as-
say. The assay utilizes a tetrazolium salt for detection of su-
peroxide radicals generated by xanthine oxidase and hapo-
xanthine. One unit of SOD is defined as the amount of 
enzyme needed to exhibit 50% dismutation of the superox-
ide radical. SOD activity was calculated and expressed as 
units per milliliter (U/mL) in plasma or units per milligram 
protein (U/mg protein) in tissue preparations.
Tissue sample preparations and western blot analysis
In order to characterize subcellular distribution of targeted 
proteins, tissue samples were processed to isolate membrane 
and cytosolic fractions as previously described.26 Briefly, 150 
mg of heart, lung, kidney and liver tissue samples were pul-
verized separately with mortar and pestle in liquid nitrogen, 
and then homogenized using a Polytron homogenizer in 1.5 
mL of cold buffer A, which contained (in mM) 50 Tris-HCl 
(pH 7.5), 5 MgC12, 10 EGTA, 2 EDTA, 1 NaHCO3, 1 PMSF, 
1 β-glycerophosphate, 1 NaF, 1 Na3VO4, and (in μg/mL) 20 
leupeptin and 4 aprotinin. The homogenate was centrifuged 
at 1000×g for 10 min at 4°C. The supernatant was collected 
and used as total tissue extracts. The supernatant was then 
further centrifuged at 100000×g for 60 min at 4°C. The su-
pernatant was removed as cytosol fractions. The pellets were 
resuspended in buffer B containing 50 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10% 
glycerol, 1 mM PMSF, 1 mM β-glycerophosphate, 60 mM 
(n=7, per group), and they were treated respectively with 
the antioxidant NAC (1.5 g/kg/day, D+NAC) or an equal 
volume of 0.9% saline (D) delivered by oral gavage. Rats 
in the non-diabetic control group (C) were treated also with 
an equal volume of 0.9% saline delivered by oral gavage. 
Treatments in all groups were continued for four weeks. 
Plasma and tissue preparations
At the end of four weeks of treatment, the rats were anti-co-
agulated with heparin (1000 IU/kg) and then anaesthetized 
with pentobarbital sodium (65 mg/kg body weight). Blood 
glucose level and body weight were measured by a Glucose 
Analyzer (Beckman Instruments, Fullerton, CA, USA) and 
a lab scale, respectively. Blood samples were collected in 
heparinized syringes by heart puncture after opening the 
thoracic cavity. The collected blood was immediately cen-
trifuged at 3000×g, plasma separated, aliquoted into small 
microcentrifuge tubes, and stored at -80°C for further de-
tection. Heart, kidney, liver and lung tissues were harvested 
immediately after sacrifice and frozen in liquid nitrogen 
and stored at -80°C for further experiments.
Inflammatory cytokines in plasma
Plasma levels of inflammatory cytokines tumor necrosis 
factor (TNF)-alpha and interleukin (IL)-6 were measured, 
using the commercially available rat ELISA kit (Bender 
Med, Vienna, Austria) according to the manufacturer’s in-
structions. 
Enzyme immunoassay (EIA) for free 15-F2t-isoprostane
15-F2t-isoprostane (15-F2t-IsoP), a specific marker of oxida-
tive stress, was measured using an EIA kit (Cayman chemi-
cal, Ann Arbor, MI, USA). Thus, plasma samples or homog-
enized heart tissue (in PBS) were purified using Affinity 
Sorbent/Column (Cayman chemical, Ann Arbor, MI, USA) 
in the presence of 0.01% butylated hydroxytoluene and then 
processed for analysis of free 15-F2t-IsoP as described.26 The 
values of plasma or tissue 15-F2t-IsoP were expressed as 
pg/mL in plasma or pg/mg protein in tissue homogenates. 
Total antioxidant activity determination
Tissue sections (50 mg) were homogenized in 1 mL of cold 
buffer (5 mM potassium phosphate, pH 7.4, containing 
0.9% sodium chloride and 0.1% glucose) and were centri-
fuged at 10000×g for 15 min at 4°C. The supernatant was 
collected for assay. Total antioxidant activity in plasma and 
tissue homogenate was measured using the Total Antioxi-NADPH Oxidase Activation in Diabetic Rats
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measurement in control rats.
Statistical analysis
The values are presented as mean±S.E.M. All biochemical 
assays were performed in duplicate and averaged before 
being analyzed. One-way or two-way analysis of variance   
was used for statistical analyses of data obtained within the 
same group and between groups, respectively. Tukey’s test 
was used for multiple comparisons of group means. Signifi-
cance was defined as p<0.05.
 
RESULTS
 
General characteristics and effects of NAC treatment
Administration of STZ resulted in characteristic symptoms 
of diabetes including hyperglycemia, and reduced body 
weight gain along with increased food and fluid intake when 
compared to age-matched controls (Table 1). Food con-
sumption, water intake and plasma glucose levels in the dia-
betic group were much higher than those in the age-matched 
control group (p<0.01). NAC treatment significantly re-
duced water intake and food consumption compared with 
the diabetic untreated group (p<0.05), but did not signifi-
cantly affect glucose levels. Body weight in the diabetic 
group was lower than that of the control group (p<0.05), 
and NAC treatment did not have significant effects on body 
weight gain (Table 1).
Octyl β-glucopyranoside, 1 mM NaF, 0.1 mM Na3VO4, and 
(in μg/mL) 20 leupeptin and 4 aprotinin. The suspensions 
were homogenized again, held on ice for 30 min, and cen-
trifuged at 100000×g for 60 min at 4°C. The supernatant 
was collected as membrane fractions. The proteins from 
each fraction (50-100 μg) were resolved via SDS-PAGE and 
subsequently transferred to PVDF membrane for immunob-
lot analysis. The membranes were blocked in 5% non fat 
milk for 2 h at room temperature, washed three times with 
TBS-T buffer each for 5 min, and then incubated overnight 
at 4°C with primary antibodies raised against Cu/Zn-SOD 
(rabbit antiserum), Mn-SOD (rabbit polyclonal IgG) (1 : 
1000, Millipore Corporation), p22phox and p67phox (rab-
bit polyclonal antibody, 1 : 500, Santa Cruz Biotechnolo-
gy), respectively. After washing three times with TBS-T for 
30 min, the blot was incubated for 1 h at room temperature 
with anti-rabbit IgG, HRP-linked antibody (1 : 10000, Cell 
Signaling). After washing the membranes, the blot was de-
veloped with enhanced chemiluminescence reagent (GE 
Healthcare) and then exposed to X-ray film. The same blot 
was stripped and reblotted with antibodies to ward GAPDH 
(1 : 2000, Cell Signaling) in total tissue extracts and cytosol 
fractions, or Na, K-ATPase (1 : 2000, Cell Signaling) in 
membrane fractions as an internal control. The intensity of 
the bands was quantified using image analysis software 
(Bio-Rad, Hercules, CA, USA), and the results were nor-
malized to corresponding internal controls to correct for 
loading. Data are presented as percent change relative to the 
Table 1. General Characteristics of Rats at the End of the Study
   C D D+NAC 
Food consumption (g/kg/day)   65.0±1.5 191.4±4.1* 146.2±3.7*
†
Water intake (mL/kg/day) 120.0±7.6   831.5±11.3* 423.8±8.5*
†
Body weight (g)   490.7±14.5   312.4±19.4*  305.8±13.3*
Plasma glucose (mM)     6.3±0.7   27.1±1.5*  25.9±1.3*
Control (C) or streptozotocin-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/
day, D+NAC) by oral gavage for four weeks. 
All values are expressed as means±S.E.M., n=7. 
*p<0.05 compared with control group. 
†p<0.05 compared with diabetic group.
Table 2. Inflammatory Cytokines at the End of the Study
C  D  D+NAC 
Plasma TNF-alpha (pg/mL) 18.5±1.1 41.2±5.5* 20.3±2.5
†
Plasma IL-6 (pg/mL) 42.7±2.7 58.0±2.4* 44.7±4.2
†
TNF, tumor necrosis factor; IL, interleukin.
Control (C) or streptozotocin-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/
day, D+NAC) by oral gavage for four weeks. 
All values are expressed as means±S.E.M., n=7. 
*p<0.05 compared with control group.
†p<0.05 compared with diabetic group.Shaoqing Lei, et al.
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pacity in tissues or in the plasma. Plasma total antioxidant 
activity in diabetic rats was higher than that of the control 
group (p<0.01) (Fig. 2A). NAC treatment significantly at-
tenuated this increase in plasma total antioxidant levels in 
diabetic rats (p<0.05, D+NAC vs. D) (Fig. 2A). Changes in 
tissue total antioxidant activity and the effects of NAC treat-
ment were tissue-specific. The total antioxidant activity in 
the heart in the diabetic group was higher than that in the 
control group (p<0.05) and was unaffected by NAC treat-
ment (Fig. 2B). In contrast, however, total antioxidant ac-
tivity in the lung, liver and kidney tissues was significantly 
decreased in the diabetic group as compared with control 
group (p<0.05) (Fig. 2B). NAC treatment elevated total an-
tioxidant activity in the lung and liver (p<0.05, D+NAC vs. 
D), but not in the kidney.
Total SOD activity in plasma and various tissues
The amount of SOD present in the cellular and extracellular 
environments is crucial for prevention of ROS mediated 
oxidative cellular damage. Plasma total SOD activity in the 
diabetic rats was much lower than that in the control group 
Inflammatory disorder
Diabetes is associated with disorders of many inflammatory 
cytokines.27 As shown in Table 2, the plasma levels of TNF-
alpha and IL-6 in diabetic rats were increased significantly 
as compared to control rats (p<0.05), which were prevented 
by treatment with NAC.
Oxidative stress marker: free 15-F2t-IsoP levels in 
plasma and tissue
Plasma (Fig. 1A) and tissue (Fig. 1B) levels of free 15-F2t-
IsoP in the diabetic group were much higher than those in 
the control group (all p<0.05 or p<0.01). NAC treatment sig-
nificantly reduced free 15-F2t-IsoP concentrations in the 
plasma and prevented the significant increase of 15-F2t-IsoP 
in the heart, lung and liver tissues seen in the diabetic group 
(all p<0.05, D+NAC vs. D). NAC significantly reduced, but 
did not normalize 15-F2t-IsoP levels in the kidney (p<0.05, 
D+NAC vs. D; p<0.05, D+NAC vs. C) (Fig. 1B). 
Total antioxidant activity in plasma and various tissues
Total antioxidant activity represents the total antioxidant ca-
Fig. 2. Effects of N-acetylcysteine treatment on the level of total antioxidant activity in plasma (A) and various tissues (B). Control (C) or 
STZ-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral ga-
vage for four weeks. Results are expressed as means±S.E.M., n=7, *p<0.05, **p<0.01 vs. C; †p<0.05 vs. D. STZ, streptozotocin.   
Fig. 1. Effects of N-acetylcysteine treatment on the level of free 15-F2t-isoprostane in plasma (A) and various tissues (B). Control (C) or 
STZ-induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral ga-
vage for four weeks. Results are expressed as means±S.E.M., n=7, *p<0.05, **p<0.01 vs. C; †p<0.05, ‡p<0.01 vs. D. STZ, streptozotocin. 
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significantly in diabetic rats as compared to age-matched 
controls (all p<0.05) (Fig. 3B), and NAC treatment pre-
vented the decrease in total SOD activity in the liver, but 
not in the kidney.
Protein expression of Cu/Zn-SOD and Mn-SOD 
In the heart and lung tissues, the levels of Cu/Zn-SOD pro-
tein in the diabetic group increased significantly compared 
with controls (all p<0.05, D vs. C) (Fig. 4A). NAC attenu-
ated this increase in Cu/Zn-SOD protein expression in the 
heart (p< 0.05, D+NAC vs. D), but did not significantly af-
fect Cu/Zn-SOD protein expression in the lung (Fig. 4A). 
In contrast, however, Cu/Zn-SOD protein expression in liv-
er and kidney tissues in diabetic rats was lower than that of 
(p<0.01) (Fig. 3A), NAC did not have significant effects on 
plasma total SOD activity. In the control rats, tissue total 
SOD activities in the heart and lung were much lower than 
those in the liver and kidney (Fig. 3B), suggesting that 
SOD might not be the predominant endogenous antioxidant 
enzyme in the heart and lung in rats under physiological 
conditions. In the heart, total SOD activity was slightly in-
creased in diabetic rats as compared to control rats (p<0.05, 
D vs. C), and this compensatory increase in SOD activity 
was not significantly affected by NAC treatment. While to-
tal SOD activity in the lung, was slightly decreased in dia-
betic rats as compared to control rats, NAC prevented the 
reduction of SOD activity in the lung. Furthermore, total 
SOD activities both in the liver and kidney were decreased 
Fig. 4. Western blots analysis of Cu/Zn-SOD and Mn-SOD protein expression in various tissues. Control (C) or STZ-induced diabetic rats 
were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for four weeks. (A) (top) 
Representative Western blot showing Cu/Zn-SOD expression with GAPDH as a loading control in total tissue extracts; (bottom, graph) 
Cu/Zn-SOD densitometric values were normalized to their corresponding GAPDH densitometric values and expressed as percent 
change relative to the measurement in control rats. (B) (top) Representative Western blot showing Mn-SOD expression with GAPDH as a 
loading control in total tissue extracts; (bottom, graph) Mn-SOD densitometric values were normalized to their corresponding GAPDH 
densitometric values and expressed as percent change relative to the measurement in control rats. All the results are expressed as 
means±S.E.M., n=7, *p<0.05, **p<0.01 vs. C; †p<0.05 vs. D. SOD, superoxide dismutase; STZ, streptozotocin.
A B
Fig. 3. Effects of N-acetylcysteine treatment on the level of total SOD activity in plasma (A) and various tissues (B). Control (C) or STZ-
induced diabetic rats were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for 
four weeks. Results are expressed as means±S.E.M., n=7 per group, *p<0.05, **p<0.01 vs. C; †p<0.05 vs. D. SOD, superoxide dismutase; 
STZ, streptozotocin.
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in various tissues. As shown in Fig. 5A, p22phox protein 
levels in the heart, lung and kidney of the diabetic group 
were significantly higher than those of the control group, 
and NAC prevented the increase of p22phox protein ex-
pression in the lung, but did not normalize their increase in 
the heart and kidney (all p<0.05, D+NAC vs. D) (Fig. 5A). 
While there was no significant difference in p22phox pro-
tein expression in the liver between control and diabetic rats, 
4 weeks of NAC treatment decreased its expression signifi-
cantly (p<0.05, D+NAC vs. D or C) (Fig. 5A).
The p67phox protein expression was significantly in-
creased both in the cytosol and membrane fractions in the 
lung, liver and kidney tissues of diabetic rats relative to 
control rats (Fig. 5B and C), reflecting increased p67phox 
activation as well as increased total protein levels which 
were in line with the increases of total p67phox protein ex-
pression in these tissues (data not shown). However, 
p67phox protein expression in the heart was significantly 
increased in the membrane fractions while markedly de-
creased in the cytosol fractions, reflecting increased 
p67phox activation. NAC prevented the increase of 
p67phox membrane translocation in the heart and liver and 
significantly attenuated the increase of p67phox membrane 
translocation in the lung and kidney tissues (all p<0.05, 
D+NAC vs. D) (Fig. 5C). 
age-matched control rats (p<0.05 in liver, p<0.01 in kidney) 
(Fig. 4A). NAC prevented the decrease of Cu/Zn-SOD pro-
tein in the liver and attenuated its reduction in the kidney 
(all p<0.05, D+NAC vs. D) (Fig. 4A).
The changes of Mn-SOD protein expression in various 
tissues were different from those of Cu/Zn-SOD. There was 
no significant difference in Mn-SOD protein expression in 
the heart tissue among control, diabetic and NAC-treated 
diabetic groups (Fig. 4B). However, Mn-SOD protein ex-
pression in both the lung and the kidney decreased signifi-
cantly in the diabetic group as compared to the control 
group, and NAC prevented the reduction of  Mn-SOD pro-
tein in the lung (p<0.05, D+NAC vs. D) but further de-
creased its level in the kidney (p<0.05, D+NAC vs. D) (Fig. 
4B). It is of an interest to note that Mn-SOD protein expres-
sion in the liver increased significantly in diabetic rats as 
compared control rats, but this increase was not affected by 
NAC treatment (Fig. 4B).
Expression of NADPH oxidase subunit: p22phox and 
p67phox
NADPH oxidase has been shown to be a major source of 
ROS production,10,28 and its subunits p22phox and p67phox 
are increased in the myocardium of STZ-induced diabetic 
rats.16 In the present study, we detected p22phox and p67phox 
Fig. 5. Western blots analysis of NADPH oxidase subunits p22phox and p67phox protein expression in various tissues. Control (C) or STZ-induced diabetic rats 
were either untreated (D) or treated with the antioxidant N-acetylcysteine (1.5 g/kg/day, D+NAC) by oral gavage for four weeks. (A) (top) Representative 
Western blot showing p22phox expression with GAPDH as a loading control in total tissue extracts; (bottom, graph) p22phox densitometric values were nor-
malized to their corresponding GAPDH densitometric values and expressed as percent change relative to the measurement in control rats. (B) (top) 
Representative Western blot showing p67phox expression with GAPDH as a loading control in cytosol fractions; (bottom, graph) p67phox densitometric values 
were normalized to their corresponding GAPDH densitometric values and expressed as percent change relative to the measurement in control rats. (C)(top) 
Representative Western blot showing p67phox expression with Na, K-ATPase as a loading control in membrane fractions; (bottom, graph) p67phox densito-
metric values were normalized to their corresponding Na, K-ATPase densitometric values and expressed as percent change relative to the measurement in 
control rats. All the results are expressed as means±S.E.M., n=7, *p<0.05, **p<0.01 vs. C; †p<0.05 vs. D. NADPH, nicotinamide dinucleotide phosphate; STZ, 
streptozotocin.
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15-F2t-isoprostane was increased despite these increases in 
systemic and heart tissue antioxidant activity. This indicates 
that up-regulation of antioxidant defenses is not sufficient 
to withstand hyperglycemia-induced increase in ROS pro-
duction. It is also worth to note that in the control rats, the 
tissue total SOD activities in the heart and lung were much 
lower than those in the liver and kidney, which may suggest 
that SOD might not be the predominant endogenous anti-
oxidant enzyme in the heart and lung in rats under physio-
logical conditions. Other endogenous antioxidant enzymes 
such as glutathione peroxidase also play important roles in 
maintaining tissue antioxidant activity in these tissues un-
der physiological conditions as well as in diabetes.36 Indeed, 
glutathione peroxidase and catalase are increased in the 
heart and lung of diabetic rats.36 This may explain the dis-
crepancy between total antioxidant activity and SOD activi-
ty in plasma observed in the current study.
NADPH oxidase, a transmembrane enzyme located in 
intracellular organelles, is one of the major sources of ROS 
in diabetes.9,10 Recent studies show that the NADPH oxi-
dase p22phox and gp91phox subunits were over-expressed 
in rat aorta,37 and that the p22phox, p47phox and p67phox 
subunits were increased in testes in STZ-induced diabetic 
rats.28 Our recent study shows that p22phox and p67phox, 
but not the p47phox, are robustly enhanced in the diabetic 
myocardium, and that NAC can prevent their increase.16 
Therefore, in the current study, we specifically examined 
the changes of p22phox and p67phox in various tissues in 
diabetic rats, and found that p22phox and p67phox subunits 
were over-expressed or activated in various tissues in early 
diabetic rats, and that NAC treatment prevented or attenuat-
ed these changes in diabetes. NAC mediated reduction of 
p67phox translocation to membrane in various tissues was 
seen in the current study. This finding is in keeping with a 
previous study showing that NAC can inhibit NADPH oxi-
dase activation.10 Thus, inhibition of NADPH oxidase over-
expression and activation and the subsequent ROS produc-
tion may represent a mechanism by which NAC reduces 
oxidative stress in diabetes in addition to its ROS scaveng-
ing property. 
Mitochondrial dysfunction is another major intracellular 
source of ROS through the mitochondrial respiratory chain 
(MRC).10 About 4% of oxygen consumed in the mitochon-
dria is converted to ROS.38 Impaired activities of enzymes in 
the MRC and mitochondrial DNA mutations were detected 
in patients with diabetes and in animal models of diabetes.39 
Mitochondrial derived superoxide anion is viewed as a sin-
DISCUSSION
We have shown in the current study that the level of 15-F2t-
IsoP, a biomarker of oxidative stress,29,30 was elevated both 
in plasma and various tissues of type 1 diabetic rats. In con-
trast to reductions in total antioxidant activity in the lung, 
liver and kidney tissues, total antioxidant activity in the 
heart was elevated in the diabetic rats accompanied by an 
increase in heart tissue total SOD activity which indicated a 
significant up-regulation of self-defense mechanisms in the 
heart. The variations in SOD activity and protein expression 
in diabetes were tissue-specific. NAC treatment up-regulat-
ed Mn-SOD protein expression in diabetic rats in the lung 
tissue, but unexpectedly reduced Mn-SOD protein expres-
sion in the kidney. The underlying mechanisms governing 
the tissue-specific effects of NAC on SOD protein expres-
sion are not clear, nevertheless, it might be due to tissue-spe-
cific effectiveness of NAC in reducing the production of su-
peroxide.16 Consequently, the organism may regulate the 
levels of SOD activation or protein expression on a basis of 
needs. It should be noted that NAC uniformly reduced the 
increase of p22phox protein expression and p67phox activa-
tion in all tissues studied, most likely inhibiting the activa-
tion of NADPH oxidase, a major source of ROS production 
in diabetes. This result is keeping with findings of a previ-
ous study which showed that NAC can inhibit NADPH ox-
idase activity in osteoblast precursor cells.31 Thus, our pres-
ent studies together with others suggest that NAC can break 
vicious cycle of ROS-induced ROS production via NADPH 
oxidase activation in diabetes. 
Increased oxidative stress can be the result of several dia-
betes-induced abnormalities, including auto-oxidation of glu-
cose, the formation of advanced glycation end products, 
and impairment of defense system.32 The impaired defense 
system is always associated with reduced antioxidant capac-
ity, abnormal activity or expression of antioxidant enzymes 
in diabetes.33-35 Among various antioxidant enzymes, SOD 
plays an important role in balancing ROS generation and 
the overall tissue antioxidant capacity. In our study, total an-
tioxidant activity and SOD activity in the lung, liver and 
kidney tissues and total SOD activity in plasma were com-
promised in diabetic rats. It should be noted total antioxi-
dant activity both in the plasma and heart tissues and total 
SOD activity in heart tissues were increased in diabetic rats, 
reflecting increased systemic antioxidant capacity overall 
and in the heart in particular. However, heart tissue level of Shaoqing Lei, et al.
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